Versus Placebo News Today : Breaking News, Live Updates & Top Stories | Vimarsana

World Metastatic Prostate Cancer Drug Landscape Research

Dublin, April 18, 2024 (GLOBE NEWSWIRE) The

Eli lillyLeuprolide mesylateOrion pharmaRoche ipatasertibMyovant biosciences relugolixCleveland biolabsMyovant biosciencesVifor freseniusJohnson astrazenecaGenentech atezolizumab tecentriqDrug administrationNerviano medical sciencesProgenics pharmaceuticals incCompany collaborations licensing partnering analysisJanssen research developmentTelix pharmaceuticals

Merck Announces Fourth-Quarter and Full-Year 2023 Financial Results

Fourth-Quarter and Full-Year Sales Reflect Sustained Growth Across Oncology and Vaccines Fourth-Quarter Worldwide Sales Were $14.6 Billion, an Increase of 6% From Fourth Quarter 2022; Excluding.

United statesAdempas verquvoPatritumab deruxtecanRobertm davisDaiichi sankyo biologicsDaiichi sankyoHuman healthAfferent pharmaceuticalsExchange commissionMerck co incRestructuring programModerna incDrug administrationNet income attributable to merck co incPrometheus biosciences incHarpoon therapeutics inc

FDA Approves Etrasimod for Moderately to Severely Active Ulcerative Colitis

The approval of oral, once-daily etrasimod 2 mg was based on positive data from the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials.

Michael chioreanEuropean medicines agencyCenter at swedish medicalDrug administrationSwedish medicalMarketing authorization applicationSeverely active ulcerative colitisVersus placeboInduction therapyEtrasimod velsipityUlcerative colitis

Horizon Therapeutics (HZNP) Announces New UPLIZNA (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2023

Horizon Therapeutics (HZNP) Announces New UPLIZNA (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Massimo filippiNeuroimmunol neuroinflammMaria roccaOrhan aktasJeffrey bennettEuropean commissionDrug administrationBrazilian health regulatory agencyResearch in multiple sclerosisAssociation of cytokineEuropean committee for treatmentHorizon therapeuticsEuropean committeeMultiple sclerosisCytokine proteinsDisease activity

Horizon Therapeutics plc Announces New UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spe

Presentations will feature data from the pivotal Phase 3 study of UPLIZNA, including new biomarker analyses DUBLIN (BUSINESS WIRE) Horizon Therapeutics plc (Nasdaq: HZNP) today announced that new UPLIZNA analyses will be presented at the 39th Congress of the European Committee for Treatment and Research in Mu.

Massimo filippiRachel vannJeffrey bennettMaria roccaNeuroimmunol neuroinflammOrhan aktasTina venturaResearch in multiple sclerosisEuropean committee for treatmentEuropean commissionBrazilian health regulatory agencyDrug administrationAssociation of cytokineProduct communicationsHorizon therapeuticsEuropean committee